George Moniz

George Moniz is an accomplished executive in the field of chemistry and biopharmaceuticals, currently serving as Executive Director at Biogen since April 2015, where responsibilities include managing a portfolio of program assets in neurodegeneration and movement disorders. Moniz has progressively advanced through roles at Biogen, leading CMC activities for key programs such as QALSODY™ and overseeing the development and lifecycle management of antisense oligonucleotides targeting ALS. Previously, Moniz held significant positions at Eisai US and Amgen, where contributions included strategic planning for drug development and leading project teams for several small molecule programs. An NIH Postdoctoral Fellow at Harvard University, Moniz holds a Ph.D. in Chemistry from Yale University and a summa cum laude BS in Chemistry from the University of Massachusetts.